A U.S. District Judge has granted class-action status to former Wyeth investors who accused the Pfizer (PFE -0.1%) unit of misleading them about risks associated with its antidepressant drug Pristiq. The FDA rejected the drug in July, 2007 over potential serious heart and liver problems associated with its use. A Pfizer spokesperson says the company will continue to defend itself vigorously.
A U.S. District Judge has granted class-action status to former Wyeth investors who accused the...
From other sites
Video at CNBC.com (Oct 29, 2015)
Video at CNBC.com (Aug 26, 2015)
Video at CNBC.com (Jul 27, 2015)
at CNBC.com (Jun 1, 2015)
at CNBC.com (May 28, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs